Summary & Overview
HCPCS J2765: Metoclopramide Injection, Up to 10 mg
HCPCS Level II code J2765 denotes the injectable formulation of metoclopramide hydrochloride, dosed up to 10 mg. This code is used nationally to bill for administration of a commonly used antiemetic and prokinetic agent across outpatient and hospital outpatient settings, emergency departments, and physician offices. Accurate use of J2765 ensures appropriate capture of drug utilization and supports clinical documentation for nausea, vomiting, and gastroparesis management.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing context, common sites of service, and the clinical role of metoclopramide in acute and outpatient care. The publication outlines typical billing considerations, common modifiers (listed separately), and what benchmark and policy topics are relevant for payers and billing professionals.
This summary provides national-level context for revenue cycle, compliance, and clinical teams responsible for injectable drug administration coding. Topics covered include benchmarking guidance, payer coverage patterns, and changes in policy or billing practice that affect use of HCPCS Level II code J2765. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2765 represents an injectable antiemetic medication, specifically metoclopramide hydrochloride, administered in doses up to 10 mg. The service is typically categorized as an injectable drug administration used for management of nausea and gastroparesis symptoms.
Service type: Medication injection / drug administration
Typical site of service: Outpatient clinic, emergency department, physician office, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A 46-year-old female presents to the emergency department with severe nausea and persistent vomiting related to diabetic gastroparesis. After triage and assessment by the emergency physician, the patient is placed on intravenous fluids and antiemetic therapy. The clinician orders an injectable prokinetic/antiemetic agent, J2765 (injection, metoclopramide HCl, up to 10 mg), to be administered intravenously for acute symptom control. The medication is typically administered by a registered nurse in the ED or inpatient medical unit. Vital signs and mental status are monitored before and after administration due to risk of extrapyramidal side effects. Documentation includes indication, dose, route (IV), time of administration, patient response, and any adverse events. Billing uses the HCPCS Level II code J2765 with an appropriate modifier based on payer rules and service circumstances. Typical sites of service include the emergency department, hospital inpatient unit, observation unit, and ambulatory infusion or procedure areas when IV antiemetic therapy is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service | Use when an E/M visit is clinically significant and distinct from administration of on the same date of service |